The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Inhibikase Therapeutics, Inc(NASDAQ:IKT) 
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease, and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a c-Abl protein kinase inhibitor for use in the treatment of P...
Share this website to your friends
Inhibikase Therapeutics Days Payable Outstanding ttm (DPO)
Inhibikase Therapeutics Days Receivable Outstanding ttm (DSO)
Inhibikase Therapeutics Op Cashflow Per Share ttm
Inhibikase Therapeutics Free Cashflow Per Share ttm
Inhibikase Therapeutics Cash Per Share ttm
Inhibikase Therapeutics P/S ratio ttm
Inhibikase Therapeutics (GAAP) P/E ratio ttm
Inhibikase Therapeutics P/B ratio ttm
No extra charts and metrics for this ticker.